162 related articles for article (PubMed ID: 33565479)
1. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.
Rupani MP; Dave JD; Parmar VB; Singh MP; Parikh KD
Natl Med J India; 2020; 33(1):10-14. PubMed ID: 33565479
[TBL] [Abstract][Full Text] [Related]
2. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions in tuberculosis and management.
Prasad R; Singh A; Gupta N
Indian J Tuberc; 2019 Oct; 66(4):520-532. PubMed ID: 31813444
[TBL] [Abstract][Full Text] [Related]
4. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
[TBL] [Abstract][Full Text] [Related]
5. Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.
Mandal A; Parthasarathy G; Burma SP; Sugunan AP; Vijayachari P
Indian J Tuberc; 2015 Jan; 62(1):23-8. PubMed ID: 25857562
[TBL] [Abstract][Full Text] [Related]
6. Adverse drug reactions & drug interactions in MDR-TB patients.
Gupta A; Kumar V; Natarajan S; Singla R
Indian J Tuberc; 2020 Dec; 67(4S):S69-S78. PubMed ID: 33308674
[TBL] [Abstract][Full Text] [Related]
7. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.
Dela AI; Tank NKD; Singh AP; Piparva KG
Lung India; 2017; 34(6):522-526. PubMed ID: 29098997
[TBL] [Abstract][Full Text] [Related]
8. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Zhou G; Luo S; He J; Chen N; Zhang Y; Cai S; Guo X; Chen H; Song C
Clin Microbiol Infect; 2024 Feb; 30(2):189-196. PubMed ID: 37741621
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.
Piparva KG; Jansari G; Singh AP
Perspect Clin Res; 2018; 9(4):165-169. PubMed ID: 30319946
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam.
Ngoc NB; Vu Dinh H; Thuy NT; Quang DV; Huyen CTT; Hoa NM; Anh NH; Dat PT; Hoa NB; Tiemersma E; Nhung NV
PLoS One; 2021; 16(9):e0255357. PubMed ID: 34492031
[TBL] [Abstract][Full Text] [Related]
12. Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis.
Tola HH; Holakouie-Naieni K; Lejisa T; Mansournia MA; Yaseri M; Tesfaye E; Mola M
PLoS One; 2019; 14(6):e0218487. PubMed ID: 31211809
[TBL] [Abstract][Full Text] [Related]
13. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
14. Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment.
Kelly AM; Smith B; Luo Z; Given B; Wehrwein T; Master I; Farley JE
Int J Tuberc Lung Dis; 2016 Apr; 20(4):442-7. PubMed ID: 26970151
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated with Non-Adherence for Prescribed Treatment in 201 Patients with Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in Anhui Province, China.
Zhu QQ; Wang J; Sam NB; Luo J; Liu J; Pan HF
Med Sci Monit; 2022 Apr; 28():e935334. PubMed ID: 35437301
[TBL] [Abstract][Full Text] [Related]
16. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
[TBL] [Abstract][Full Text] [Related]
17. Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study.
Nilamsari WP; Rizqi MF; Regina NO; Wulaningrum PA; Fatmawati U
J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):783-787. PubMed ID: 34214373
[TBL] [Abstract][Full Text] [Related]
18. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India.
Hire R; Kale AS; Dakhale GN; Gaikwad N
Mediterr J Hematol Infect Dis; 2014; 6(1):e2014061. PubMed ID: 25237474
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Multidrug-resistant Tuberculosis.
Rumende CM
Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.
Dzeyie KA; Basu S; Dikid T; Bhatnagar AK; Chauhan LS; Narain JP
Indian J Tuberc; 2019 Jul; 66(3):331-336. PubMed ID: 31439176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
